Traws Pharma, Inc. (TRAW) – What Are Analysts Thinking About This Stock?

Shares of Traws Pharma, Inc. (NASDAQ:TRAW) have been assigned a consensus recommendation of “Reduce” from the five brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $1.00.

Several research analysts have recently weighed in on TRAW shares. HC Wainwright reiterated a “neutral” rating and set a $1.00 price target on shares of Traws Pharma in a research note on Tuesday, August 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Traws Pharma in a research note on Wednesday, August 26th.

Traws Pharma Trading Up 11.1%

Traws Pharma stock opened at $0.25 on Thursday. The business’s 50 day simple moving average is $0.44 and its 200 day simple moving average is $1.09. Traws Pharma has a 12 month low of $0.22 and a 12 month high of $3.23. The company has a market cap of $3.84 million, a price-to-earnings ratio of -0.14 and a beta of 1.67.

Traws Pharma (NASDAQ:TRAW) last released its earnings results on Friday, August 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.18. As a group, equities research analysts forecast that Traws Pharma will post -1.20 earnings per share for the current fiscal year.

About Traws Pharma

Traws Pharma, Inc. is a clinical-stage biotechnology company focused on developing antiviral medicines for respiratory viral infections, including influenza and COVID-19. The company’s approach includes developing therapies designed to act against viral replication and host-cell pathways involved in disease progression. Traws Pharma’s pipeline includes zapnometinib, an investigational oral host-directed antiviral designed to inhibit the MEK signaling pathway, which may support treatment across multiple strains of influenza and coronaviruses.